Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Servier has completed the acquisition of Day One Biopharmaceuticals, a medical devices business in the United States, for $2.5 billion. Servier acquires Day One Biopharmaceuticals to expand healthcare capabilities tied to medical devices and biopharmaceutical innovation. Day One Biopharmaceuticals acquisition supports product development and commercialization efforts across healthcare M&A priorities. The Servier acquisitions are structured as a platform acquisition and are categorized as a strategic acquisition by a strategic buyer, with deal size over $100M and a closed status.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026